$CGC

Canopy Growth Corp

Canopy Growth produces, distributes and sells cannabis and cannabis-related products for medical and adult use under a portfolio of brands. Its products include dried flower, pre-rolls, oils, softgels, extracts, concentrates, edibles and vapes. Through Spectrum Therapeutics, Canopy Medical and other medical brands, it serves patients in Canada and select international markets; its adult-use brands sell through established retail distribution systems across Canadian provinces and territories. The company also makes and sells herbal vaporizer devices through Storz & Bickel, whose products reach over 100 markets. It operates in Canada, Europe and Australia and holds a significant non-controlling, non-voting interest in Canopy USA, which participates in U.S. cannabis sales. Canopy Growth earns money from sales of cannabis products, medical services and vaporizer devices, including products sold online to registered patients. Its medical services include virtual consultations and patient support through clinic banners such as Apollo, Canada House and Abba Medix. Its headquarters are in Smiths Falls, Ontario.

No enriched coverage for $CGC in the last 7 days.

No SEC Form 4 filings for $CGC in the last 30 days.

See all $CGC insider activity →
Low

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Organigram to acquire Aurora Cannabis for C$561M (US$400M), creating a global cannabis leader. Canopy Growth reports 22% revenue growth, driven by international sales. Key tickers: OGI, ACB, CGC, BTI, CURA, CURLF, WEED.

Which of These 5 Cannabis Stocks Has the Strongest Balance Sheet?

Tilray (TLRY), Canopy Growth (CGC), Cronos (CRON), SNDL (SNDL), and Aurora Cannabis (ACB) were analyzed for balance sheet strength. Cronos leads with $841M in cash and no debt, while SNDL is debt-free with positive cash flow. Tilray and Canopy still face financial challenges, and Aurora has smaller reserves.

CGC sentiment & insider activity

Recent CGC coverage spans earnings, corporate actions and regulation.

What's driving CGC

AlphAI scores every news story that mentions CGC with an AI model for sentiment and relevance, and aggregates insider trades from Canopy Growth Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CGC

Score
$CGCMedEarnings

Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results

Canopy Growth Corp (CGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets Cannabis Net revenue growth of 30% in Cannabis segment 18% growth in Canada medical cannabis revenue and 17% growth in C

Canopy Growth Shareholders Approve Discretionary 1-for-5 to 1-for-15 Reverse Split

Canopy Growth (CGC) shareholders approved a discretionary 1-for-5 to 1-for-15 reverse share split, among other proposals, at their 2026 annual meeting. The board can execute the split at any ratio within the range before September 25, 2027. A reverse split reduces shares outstanding and raises the per-share price without changing economic value. Shareholders also elected directors, appointed an auditor, and approved other proposals.

$CGCLowShareholder vote

Canopy Growth Corp (CGC): Submission of Matters to a Vote of Security Holders

Canopy Growth Corp (CGC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 25, 2026, Canopy Growth Corporation (“ Canopy Growth ”) convened and adjourned to, and reconvened on, October 23, 2026, its 2026 Annual General and Special Meeting of Shareholders (the “ Annual Meeting ”

Related tickers